HC Wainwright & Co. Initiates Coverage On Atossa Therapeutics with Buy Rating, Announces Price Target of $4
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Atossa Therapeutics (NASDAQ:ATOS) with a Buy rating and a price target of $4.
February 12, 2024 | 12:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Atossa Therapeutics receives a Buy rating from HC Wainwright & Co. with a price target of $4.
Analyst ratings, especially from reputable firms like HC Wainwright & Co., can significantly influence investor sentiment and stock prices. A Buy rating suggests a positive outlook on the stock, potentially leading to increased investor interest and a rise in stock price in the short term. The announcement of a specific price target provides a benchmark for expectations and can further bolster investor confidence in the stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100